Qube Holdings (ASX:QUB) Agrees to A$11.7bn Macquarie Takeover- Buy for the Payout or Take Profits Now?

Ujjwal Maheshwari Ujjwal Maheshwari, February 17, 2026

Qube Holdings M&A: What the Macquarie Bid Means

Qube Holdings (ASX: QUB) hit a record high on Monday after signing a binding deal with a Macquarie Asset Management-led consortium at A$5.20 per share, valuing Australia’s largest integrated logistics provider at roughly A$11.7 billion. The offer is a 27.8% premium to Qube’s pre-approach price and marks one of the largest Australian take-private deals since Blackstone bought AirTrunk in 2024. With shares sitting around A$5.01, investors face a straightforward question: hold for the final payout, or take profits now?

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

Why Macquarie Is Paying a Big Premium for Ports and Rail

Macquarie isn’t paying up for what Qube Holdings earns today; it’s paying for what these assets are worth over the next 20 to 30 years.

Qube Holdings owns ports, rail networks, terminals, and bulk handling operations across Australia, New Zealand, and Southeast Asia. You can’t build a competing port next door. These assets generate steady cash flows with natural pricing power, exactly what pension funds want to own.

The consortium tells the story. Alongside Macquarie, the group includes Pontegadea, the family office of Zara founder Amancio Ortega, plus UniSuper, Brighter Super, and Mercer. Pontegadea buys assets it plans to hold for decades, signalling this is a long-term infrastructure play, not a quick financial flip.

Perhaps the strongest signal comes from UniSuper. As Qube’s largest shareholder with a 15% stake, the super fund chose to roll its holding into the new private structure rather than take the cash. In other words, UniSuper thinks Qube is worth more than A$5.20 over time.

Should You Buy the Spread or Sell Now?

With shares around A$5.01 and the offer at A$5.20, the gap works out to roughly 3.5%. One detail worth noting: Qube Holdings is permitted to pay up to A$0.40 per share in dividends before the deal closes, which gets deducted from the A$5.20 cash price.

However, those dividends are expected to be franked, meaning Australian tax residents could receive up to 17 cents per share in franking credits, effectively making the total package worth slightly more than the headline number. The shareholder vote is expected around June 2026, so that annualises to around 10%, not bad for what looks like a fairly low-risk trade.

The deal is fully funded with no financing condition, and if completion drags past December 2026, Macquarie has agreed to pay a ticking fee of 2 cents per share per month, so investors are compensated for any delay. We believe that Macquarie has navigated complex regulatory approvals many times before. That said, sign-offs are still needed from FIRB, the ACCC, and regulators in New Zealand and Papua New Guinea. If any hit a snag, shares could dip below A$5. For existing holders, sitting tight makes sense. Conservative investors may prefer to simply take their gains now.

Which ASX Infrastructure Stocks Could Be Next?

The Qube Holdings deal sends a clear message: private capital is hungry for Australian infrastructure and willing to pay premium prices.

On the same day, Aurizon (ASX: AZJ) scrapped plans to sell a stake in its Queensland coal rail network, choosing to keep full ownership after reporting strong half-year earnings and lifting its dividend by 36%. Management clearly sees more long-term value in holding these assets than selling them. Meanwhile, Brambles (ASX: BXB), the global logistics company behind the CHEP pallet network, operates across 60 countries with a dominant position that’s extremely hard to replicate, exactly the kind of business that attracts long-term private capital.

With supply chains restructuring and Australian resources in high demand, logistics and infrastructure assets are being repriced. The Qube Holdings takeover is the biggest deal, but we doubt it will be the last.

Blog Categories

Get Our Top 5 ASX Stocks for FY26

Recent Posts

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, its never looked back and is more than a one-trick pony!

Investors may remember Rhythm Biosciences (ASX:RHY) for its ColoSTAT test, but it is Genetype that is arguably more exciting. The…

GPT Group (ASX:GPT): Still hasn’t surpassed pre-COVID levels, but is it finally out of the doldrums now?

GPT Group (ASX:GPT) released its annual results (for CY25) yesterday, but the market reaction was nuanced and it remains below…

JORC Resources: Here’s What’s Crucial For Investors to Know Before Investing

Investors will often hear of JORC Resources or a JORC Code and may think companies are alluding to a mere…